Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.515 USD | +3.56% | -4.61% | +37.19% |
Financials (USD)
Sales 2024 * | 833K | Sales 2025 * | 4.6M | Capitalization | 342M |
---|---|---|---|---|---|
Net income 2024 * | -127M | Net income 2025 * | -136M | EV / Sales 2024 * | 336 x |
Net cash position 2024 * | 61.98M | Net cash position 2025 * | 61.76M | EV / Sales 2025 * | 61 x |
P/E ratio 2024 * |
-2.77
x | P/E ratio 2025 * |
-2.78
x | Employees | 140 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.29% |
Latest transcript on Tenaya Therapeutics, Inc.
1 day | -1.36% | ||
1 week | +2.59% | ||
Current month | -3.96% | ||
1 month | -2.02% | ||
3 months | -16.48% | ||
6 months | +146.33% | ||
Current year | +34.57% |
Managers | Title | Age | Since |
---|---|---|---|
Faraz Ali
CEO | Chief Executive Officer | 51 | 18-05-31 |
Leone Patterson
DFI | Director of Finance/CFO | 61 | 21-05-31 |
Kee-Hong Kim
CTO | Chief Tech/Sci/R&D Officer | - | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Williams
BRD | Director/Board Member | 75 | 16-09-30 |
David Goeddel
CHM | Chairman | 72 | 16-07-31 |
Jeffrey Walsh
BRD | Director/Board Member | 58 | 20-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.53% | - | |
0.00% | 17 M€ | +4.66% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 4.435 | +1.72% | 55 167 |
24-05-23 | 4.36 | -1.36% | 283,371 |
24-05-22 | 4.42 | +5.74% | 329,156 |
24-05-21 | 4.18 | -1.65% | 1,007,150 |
24-05-20 | 4.25 | -8.80% | 267,116 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.57% | 342M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.72% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- TNYA Stock